Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra Lifesciences Holdings Corp (IART) delivers innovative medical solutions for neurosurgery, orthopedic care, and tissue regeneration. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s advancements in surgical technology and patient care.
Access consolidated information on FDA clearances, product innovations, and strategic partnerships that shape modern surgical practices. Our repository includes earnings reports, regulatory milestones, and leadership updates critical for understanding IART’s market position.
Key content categories cover developments in Codman Specialty Surgical instruments, Tissue Technologies advancements, and operational updates from global manufacturing facilities. Stay informed about technologies enhancing neurosurgical monitoring and extremity repair solutions.
Bookmark this page for streamlined access to Integra’s verified press releases and analysis. Check regularly for updates driving progress in surgical precision and regenerative medicine across 100+ countries.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its 2022 financial results, revealing fourth quarter revenues of $398.0 million, a 1.8% decrease year-over-year, but a 2.9% organic growth. GAAP earnings per diluted share rose to $0.63 from $0.53 in Q4 2021. For the full year, revenues reached $1,557.7 million, a 1.0% increase, with GAAP EPS at $2.16. The company provided guidance for 2023, expecting revenues of $1,602 million to $1,620 million and adjusted EPS between $3.43 and $3.51, indicating optimism for growth as markets recover from COVID-19 impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its fourth quarter 2022 financial results on February 22, 2023, before the market opens. A conference call with the management team is scheduled for 8:30 a.m. ET on the same day. This event will be accessible via a live webcast on the company's investor website. Integra is recognized as a leader in regenerative tissue technologies and neurosurgical solutions, providing a wide range of high-quality products to enhance patient care. Investors can find further details and register for the call on their official site.
Campbell Soup Company (NYSE:CPB) announced the appointment of
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced preliminary financial results for the fourth quarter and full-year 2022, revealing expected revenues of $397-$398 million for Q4, a 2% decrease reported but a 3% organic increase year-over-year. For the full year, revenues are projected at $1,557-$1,558 million, reflecting a 1% reported increase and 4% organic growth. Adjusted earnings per diluted share for both periods are expected to exceed prior guidance. The company also plans a $150 million share repurchase program in 2023 and will present at the J.P. Morgan Healthcare Conference on January 11.
Integra LifeSciences (NASDAQ: IART) announced that its CEO, Jan De Witte, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 PM ET. A live webcast will be accessible through Integra's investor relations website. The company, recognized for its regenerative tissue technologies and neurosurgical solutions, aims to support clinicians in delivering optimal patient care. Integra boasts a robust portfolio of high-quality brands.
Integra LifeSciences (NASDAQ:IART) has completed its acquisition of Surgical Innovation Associates (SIA). This strategic move aims to enhance Integra's position as a leader in implant-based breast reconstruction (IBBR) procedures, as stated by Robert T. Davis, Jr., Executive VP at Integra. The company emphasizes its commitment to improving patient outcomes through innovative technologies. Integra is known for its extensive portfolio in regenerative tissue technologies and neurosurgical solutions, promising a focus on high-quality patient care.
Integra LifeSciences (NASDAQ:IART) announced the acquisition of Surgical Innovation Associates (SIA) for $50 million, with potential additional payments totaling $90 million based on performance metrics. This strategic acquisition enhances Integra's product offerings in plastic and reconstructive surgery, particularly in breast reconstruction, addressing a growing market opportunity. The FDA is currently reviewing Integra's pre-market approval application for its existing SurgiMend product, and the transaction is expected to be dilutive to earnings in year one but accretive by year three.
Integra LifeSciences (Nasdaq: IART) has reached a definitive agreement to acquire Surgical Innovation Associates (SIA) for up to
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q3 2022 revenues of $385 million, a decrease of 0.4% year-over-year, with a 3.5% increase on an organic basis. GAAP earnings per diluted share rose to $0.60, compared to $0.51 last year. The company raised its EPS outlook to $3.29-$3.33 and reaffirmed revenue guidance between $1,551-$1,563 million, indicating organic growth of 3.7%-4.5%. The TWC business was sold for $28.8 million, and cash flow from operations reached $68 million. Full-year guidance reflects adjustments due to foreign currency impacts.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) plans to release its third quarter 2022 financial results on October 26, 2022, before market opening. This will be followed by a conference call hosted by the management team at 8:30 a.m. ET. Investors can access the call by dialing 866-571-0905 with passcode 1121226# or through a live webcast on the company’s website. A replay will be available until November 7, 2022.
